Polycystic Ovary Syndrome
Challenging Issues in the Modern Era of Individualized Medicine
- 1st Edition - November 25, 2021
- Imprint: Elsevier
- Editor: Evanthia Diamanti-Kandarakis
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 0 4 5 - 9
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 3 0 4 6 - 6
Women’s healthcare regarding polycystic ovarian syndrome remains challenging. Patients often go from one specialist to another trying to fully understand and management the… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteWomen’s healthcare regarding polycystic ovarian syndrome remains challenging. Patients often go from one specialist to another trying to fully understand and management the disorder. Women often go years before a diagnosis, seeing three or more doctors before a confirmed diagnosis. Polycystic Ovarian Syndrome: Challenging Issues in the Modern Era of Individualized Medicine brings together multiple medical disciplines to improve the care of women with PCOS. Such a multidisciplinary clinical and scientific approach integrates obstetrics and gynecology, pediatric and medical endocrinology, internal medicine, genetics, psychology and laboratory medicine into relevant translational clinical and scientific discussions that update both the scientific understanding of PCOS and the diagnosis and management of all aspects of the syndrome. The impact of PCO on the onset of puberty is subdivided in sub sections to get a better understanding of this condition and the management at different stages in a woman’s life.
- Represents an unparalleled compilation of chapters from experts in the field relevant to contemporary polycystic ovarian syndrome
- Covers aspects such as obesity, metabolic changes, and emotional changes associated with PCOS
- Highlights contemporary management and the current understanding of this unique syndrome with a comprehensive and fresh approach
Readership includes physicians, nurses and healthcare providers in the fields of family medicine, internal medicine, endocrinology, obstetrics and gynecology, reproductive endocrinology, dermatology, psychiatry and surgery
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Author biography
- Part I: Polycystic ovary syndrome: Challenges and controversies
- Chapter 1: Defining PCOS: A syndrome with an intrinsic heterogeneous nature
- Abstract
- Introduction
- Etiology and pathophysiology of PCOS
- Historical definitions of PCOS: Cause or consequence of heterogeneity?
- Strategies to overcome the limitations imposed by the heterogeneity of PCOS
- References
- Chapter 2: Secondary PCOS: Well-defined causes, leading to the PCOS phenotype
- Abstract
- Acknowledgments
- Introduction
- PCOS—Secondary to hyperprolactinemia
- PCOS—Secondary to thyroid disorders
- PCOS—Secondary to nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- PCOS—Secondary to cushing syndrome
- PCOS—Secondary to acromegaly
- PCOS—Secondary to severe insulin resistance states
- References
- Chapter 3: Developmental origins of polycystic ovary syndrome: Everything starts in utero
- Abstract
- Acknowledgments
- Introduction
- PCOS phenotypes: Reproductive and metabolic components
- PCOS genetics
- Recent genetic studies re-categorize PCOS women into etiologically disparate reproductive and metabolic phenotypes
- Hyperandrogenism in PCOS redefined
- Intergenerational transmission of PCOS
- Gestational hyperandrogenism in PCOS
- Pre- and peri-pubertal hyperandrogenism in PCOS
- PCOS-like traits in hyperandrogenic animal models
- Conclusions
- References
- Chapter 4: The multifarious role of insulin in PCOS: From pathophysiology to therapeutic management
- Abstract
- Introduction
- Difficulties and pitfalls in the measurement of in vivo insulin action
- The unhealthy connection between insulin and PCOS
- Insulin resistance or hyperinsulinemia: Which is the player in the pathophysiology of PCOS?
- Effects of treatment of hyperinsulinemia/insulin resistance in women with PCOS
- Conclusions
- References
- Chapter 5: The pathogenic role of androgen excess in PCOS
- Abstract
- Introduction
- PCOS clinical aspects
- Androgens in PCOS
- Pathophysiology of PCOS
- The androgenic hypothesis in the pathogenesis of PCOS
- The effect of antiandrogens
- Studies on animal models
- Prenatal and early postnatal androgen exposure
- Metabolic effects of elevated androgens
- References
- Chapter 6: Intrinsic abnormalities of adipose tissue and adipose tissue dysfunction in PCOS
- Abstract
- Introduction
- Intrinsic abnormalities of adipose tissue and adipose tissue dysfunction in PCOS
- Body fat distribution, insulin resistance, androgen secretion, and adipose tissue dysfunction across PCOS phenotypes
- Epigenetics of adipose tissue in PCOS
- References
- Chapter 7: Diet and exercise in the management of PCOS: Starting from the basics
- Abstract
- Obesity, insulin resistance and metabolic syndrome in PCOS
- Energy expenditure in PCOS
- Interventions aiming at weight loss in patients with PCOS
- Key points
- References
- Chapter 8: Targeting metabolism in the management of PCOS: Metformin and beyond
- Abstract
- Metabolic dysfunction in PCOS
- Interventions targeting metabolism in PCOS
- Conclusions
- Future perspectives
- References
- Chapter 9: Combined oral contraceptives: Why, when, where?
- Abstract
- Introduction
- Pharmacology of COCs
- Side effects and contraindications of therapy with COCs
- Why treat PCOS with COCs?
- When treat PCOS with COCs?
- Where treat PCOS with COCs
- Side effects of treating PCOS with COCs
- Conclusion
- References
- Chapter 10: Targeting infertility in PCOS: Unfolding “Ariadne's thread”
- Abstract
- Introduction
- Etiologies for infertility associated with PCOS
- Pretreatment health enhancement
- Medical and surgical ovulation induction
- Insulin sensitizers
- The future
- Algorithm for the management of anovulatory PCOS [2]
- References
- Chapter 11: Inositols and other supplements in the management of PCOS
- Abstract
- Introduction
- Inositols
- Hormone D (vitamin D)
- Alpha-lipoic acid
- Omega 3
- Melatonin
- Probiotics
- Conclusions
- References
- Chapter 12: Polycystic ovary syndrome and nonalcoholic fatty liver disease
- Abstract
- Overview of metabolic risk profile and complications of NAFLD
- Epidemiological aspects of NAFLD in PCOS
- Putative pathophysiological pathways linking PCOS to NAFLD
- Therapeutic options of NAFLD in PCOS
- Conclusions
- References
- Chapter 13: Cardiometabolic risk in women with PCOS
- Abstract
- Introduction
- CV risk factors in different PCOS phenotypes
- Influence of obesity on CV and metabolic risk of PCOS
- Changes of hormonal production and CV risk factors in women with PCOS moving from young to late reproductive age
- CV events in aged PCOS
- Conclusions
- References
- Part II: PCOS and pregnancy: Current concepts?
- Chapter 14: Endocrine-disrupting chemicals and PCOS: A novel contributor in the etiology of the syndrome
- Abstract
- Introduction
- Overview of endocrine disruptors: Basic concepts and key characteristics
- Endocrine disruptors and PCOS: A complex and multifarious relationship
- Moving from the pathogenetic background to therapeutic implications—Future perspectives
- Conclusions
- References
- Chapter 15: Long-term health in women of age more than 40 years with polycystic ovary syndrome
- Abstract
- Introduction
- The aging PCOS phenotypes
- Diagnosis of PCOS in menopause
- Clinical manifestations of PCOS
- Monitoring
- Management
- Conclusions
- References
- Chapter 16: Vitamin D metabolism in polycystic ovary syndrome (PCOS)
- Abstract
- Vitamin D metabolism
- Vitamin D and female reproductive physiology
- Vitamin D and PCOS
- Conclusions
- References
- Chapter 17: The challenging role of antiandrogens in the management of polycystic ovary syndrome
- Abstract
- Introduction (why to use antiandrogens)
- Antiandrogenic progestins
- Spironolactone
- Flutamide and bicalutamide
- Finasteride and dutasteride
- Topical antiandrogens
- Combination therapy
- Personalized medicine
- Conclusions
- Conflicts of interest
- References
- Chapter 18: PCOS in adolescence_ Pathophysiology, diagnostic challenges, and therapeutic controversies
- Abstract
- Introduction
- Concluding remarks
- References
- Chapter 19: Obstructive sleep apnea and polycystic ovary syndrome: Clinical interactions and underlying pathophysiology
- Abstract
- Introduction
- Prevalence of OSA in women with PCOS
- Impact of OSA in women with PCOS
- Risk factors and potential underlying pathophysiologic mechanisms linking OSA and PCOS
- Conclusion and future research directions
- References
- Index
- Edition: 1
- Published: November 25, 2021
- Imprint: Elsevier
- No. of pages: 350
- Language: English
- Paperback ISBN: 9780128230459
- eBook ISBN: 9780128230466
ED
Evanthia Diamanti-Kandarakis
Dr. Daniel Dumesic, MD, Professor of Reproductive Endocrinology and Infertility in the Department of Obstetrics and Gynecology at UCLA, Los Angeles, CA. A focus of his clinical research is on polycystic ovarian syndrome, dedicating his time and career to advancing research in this field. He has published extensively on metabolic diseases and their negative impact on female reproduction.
Affiliations and expertise
Professor of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, UCLA, Los Angeles, CA, USARead Polycystic Ovary Syndrome on ScienceDirect